María Lorenzo-González1, Alberto Ruano-Ravina2, María Torres-Durán3, Karl T Kelsey4, Mariano Provencio5, Isaura Parente-Lamelas6, Virginia Leiro-Fernández3, Iria Vidal-García7, Olalla Castro-Añón8, Cristina Martínez9, Antonio Golpe-Gómez10, Maruxa Zapata-Cachafeiro11, María Piñeiro-Lamas12, Mónica Pérez-Ríos13, José Abal-Arca6, Carmen Montero-Martínez7, Alberto Fernández-Villar3, Juan M Barros-Dios14. 1. Service of Preventive Medicine, University Hospital Complex of Ourense, Spain; Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain. 2. Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Department of Epidemiology, Brown School of Public Health, Brown University, Providence, RI, USA. Electronic address: alberto.ruano@usc.es. 3. Service of Neumology, University Hospital Complex of Vigo, Spain. 4. Department of Epidemiology, Brown School of Public Health, Brown University, Providence, RI, USA. 5. Service of Oncology, Puerta de Hierro University Hospital, Madrid, Spain. 6. Service of Neumology, University Hospital Complex of Ourense, Spain. 7. Service of Neumology, University Hospital Complex of A Coruña, Spain. 8. Service of Neumology, Hospital Lucus Augusti, Lugo, Spain. 9. National Institute of Silicosis, University Hospital of Asturias, Oviedo, Spain. 10. Service of Neumology, University Hospital Complex of Santiago de Compostela, Spain. 11. Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain. 12. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain. 13. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Department of Epidemiology, Brown School of Public Health, Brown University, Providence, RI, USA. 14. Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Service of Preventive Medicine, University Hospital Complex of Santiago de Compostela, Spain.
Abstract
BACKGROUND: Using a pooled case-control study design, including only never-smokers, we have assessed the association of residential radon exposure with the subsequent occurrence of lung cancer. We also investigated whether residential radon poses a different risk specifically for adenocarcinoma. METHODS: We pooled individual data from different case-control studies conducted in recent years in Northwestern Spain which investigated residential radon and lung cancer. All participants were never-smokers. Cases had a confirmed biopsy of primary lung cancer. Hospital controls were selected at pre-surgery units, presenting for non-complex surgical procedures. They were interviewed using a standardized instrument. Residential radon was measured using alpha track detectors at the Galician Radon Laboratory at the University of Santiago de Compostela. RESULTS: A total of 1415 individuals, 523 cases and 892 controls were included. We observed an odds ratio of 1.73 (95%CI: 1.27-2.35) for individuals exposed to ≥ 200 Bq/m3 compared with those exposed to ≤100 Bq/m3. Lung cancer risk for adenocarcinoma was 1.52 (95%CI: 1.14-2.02) using the same categories for radon exposure. CONCLUSIONS: Residential radon is a clear risk factor for lung cancer in never-smokers. Our data suggest that radon exposure is associated with all histological types of lung cancer and also with adenocarcinoma, which is currently the most frequent histological type for this disease.
BACKGROUND: Using a pooled case-control study design, including only never-smokers, we have assessed the association of residential radon exposure with the subsequent occurrence of lung cancer. We also investigated whether residential radon poses a different risk specifically for adenocarcinoma. METHODS: We pooled individual data from different case-control studies conducted in recent years in Northwestern Spain which investigated residential radon and lung cancer. All participants were never-smokers. Cases had a confirmed biopsy of primary lung cancer. Hospital controls were selected at pre-surgery units, presenting for non-complex surgical procedures. They were interviewed using a standardized instrument. Residential radon was measured using alpha track detectors at the Galician Radon Laboratory at the University of Santiago de Compostela. RESULTS: A total of 1415 individuals, 523 cases and 892 controls were included. We observed an odds ratio of 1.73 (95%CI: 1.27-2.35) for individuals exposed to ≥ 200 Bq/m3 compared with those exposed to ≤100 Bq/m3. Lung cancer risk for adenocarcinoma was 1.52 (95%CI: 1.14-2.02) using the same categories for radon exposure. CONCLUSIONS: Residential radon is a clear risk factor for lung cancer in never-smokers. Our data suggest that radon exposure is associated with all histological types of lung cancer and also with adenocarcinoma, which is currently the most frequent histological type for this disease.
Authors: Cheng Peng; Natalie DuPre; Trang VoPham; Yujing J Heng; Gabrielle M Baker; Christopher A Rubadue; Kimberly Glass; Abhijeet Sonawane; Oana Zeleznik; Peter Kraft; Susan E Hankinson; A Heather Eliassen; Jaime E Hart; Francine Laden; Rulla M Tamimi Journal: BMC Cancer Date: 2020-07-28 Impact factor: 4.430
Authors: Irene Calvente; María Isabel Núñez; Rachid Chahboun Karimi; Juan Villalba-Moreno Journal: Int J Environ Res Public Health Date: 2021-03-11 Impact factor: 3.390
Authors: Ana Casal-Mouriño; Alberto Ruano-Ravina; María Torres-Durán; Isaura Parente-Lamelas; Mariano Provencio-Pulla; Olalla Castro-Añón; Iria Vidal-García; José Abal-Arca; María Piñeiro-Lamas; Alberto Fernández-Villar; Luis Valdés-Cuadrado; Juan Miguel Barros-Dios; Mónica Pérez-Ríos Journal: Sci Rep Date: 2020-12-03 Impact factor: 4.379
Authors: Alberto Ruano-Ravina; Mariano Provencio; Virginia Calvo de Juan; Enric Carcereny; Anna Estival; Delvys Rodríguez-Abreu; Gretel Benítez; Rafael López-Castro; Marta Belver; María Guirado-Risueño; Carlos Guirao-Rubio; Ana Blasco; Bartomeu Massutí; Ana Laura Ortega; Manuel Cobo; Joaquín Mosquera-Martínez; Carlos Aguado de la Rosa; Joaquim Bosch-Barrera; Amparo Sánchez-Gastaldo; Edel Del Barco Morillo; Óscar Juan; Manuel Dómine; José Manuel Trigo; Diego Pereiro Corbacho; Juana Oramas Journal: Transl Lung Cancer Res Date: 2021-10
Authors: Natasha L Cholowsky; Jesse L Irvine; Justin A Simms; Dustin D Pearson; Weston R Jacques; Cheryl E Peters; Aaron A Goodarzi; Linda E Carlson Journal: Sci Rep Date: 2021-06-07 Impact factor: 4.379
Authors: Thomas F Monaghan; Syed N Rahman; Christina W Agudelo; Alan J Wein; Jason M Lazar; Karel Everaert; Roger R Dmochowski Journal: Int J Environ Res Public Health Date: 2021-05-25 Impact factor: 3.390
Authors: Fintan K T Stanley; Jesse L Irvine; Weston R Jacques; Shilpa R Salgia; Daniel G Innes; Brandy D Winquist; David Torr; Darren R Brenner; Aaron A Goodarzi Journal: Sci Rep Date: 2019-12-03 Impact factor: 4.379
Authors: Nipuni Nilakshini Wimalasena; Alice Chang-Richards; Kevin I-Kai Wang; Kim N Dirks Journal: Int J Environ Res Public Health Date: 2021-03-10 Impact factor: 3.390